Catalog No.
DHE48301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2-lambda
Clonality
Monoclonal
Target
hN1, TAN1, NEXT, NICD, Notch 1, Neurogenic locus notch homolog protein 1, Translocation-associated notch protein TAN-1, NOTCH1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P46531
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
OMP-52M51, CAS: 1447814-75-6
Clone ID
Brontictuzumab
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors, PMID: 29726923
A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma, PMID: 33004830
Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival, PMID: 29858025
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors, PMID: 27870570
Clinical Outcomes With Notch Inhibitors in Notch-Activated Recurrent/Metastatic Adenoid Cystic Carcinoma., PMID:40025676
A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma., PMID:33004830
Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival., PMID:29858025
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors., PMID:29726923
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors., PMID:27870570
For research use only. Not for human or drug use.
